Treace Medical price target lowered to $7.50 from $12 at Lake Street

Lake Street analyst Ben Haynor lowered the firm’s price target on Treace Medical (TMCI) to $7.50 from $12 and keeps a Buy rating on the shares. A roughly 10% sales decline is now implied for Q4 where the firm and consensus had previously modeled growth of about 13%, notes the analyst, who adds that there is “no question updated guidance for FY2025 represented a massive disappointment.”